Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY **PATENT APPLICATION**

TCS-411.1P US-1 Attorney Docket No. Rittershaus and Thomas First Inventor MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY

**TRANSMITTAL** 

(Only for new nonprovision	nal applications under 37 CFR 1.53(b)	) E	xpress	Mail Label No.	EL1	6433	35375US
APPLICATION ELEMENTS			ADDRESS TO: Assistant Commissioner for Patents Box Patent Application				
	seming utility patent application conter	nts.	L <u></u>		Washington,	DC 20	)231
1. Fee Transmittal For Submu an original and a Applicant claims see 37 CFR 1.27.				CD-ROM or CD- Computer Progra eotide and/or Amino pplicable, all necess	am ( <i>Appendi.</i> o Acid Seque	x)	
3. Specification (preferred arrangement)			a. 🚺	Computer Read		CRF)	
- Descriptive title	of the invention e to Related Applications		b. S	pecification Sequer	nce Listing o	n:	
<ul> <li>Statement Reg</li> </ul>	arding Fed sponsored R & D			i. CD-ROI	M or CD-R (2	2 copie	es); or
- Reference to se	quence listing, a table,			ii. 🗶 paper	·	-	
	rogram listing appendix		ء ٦	X Statements ver	rifuina idontit	u of ah	novo conios
<ul> <li>Background of</li> <li>Brief Summary</li> </ul>				· · · · · · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·
<ul> <li>Brief Descriptio</li> </ul>	n of the Drawings (if filed)			<u>CCOMPANYIN</u>	G APPLIC	ATIC	ON PARTS
- Detailed Descri	ption	OLD	' <del>-1</del> 79. 🔰	🚺 Assignment Par	ers (cover s	heet 8	document(s))
<ul><li>Claim(s)</li><li>Abstract of the</li></ul>	Disclosure		10.	37 CFR 3.73(b) (when there is a			Power of Attorney
4. <b>X</b> Drawing(s) (35 U	.S.C. 113)   Total Sheets   12	1	11.	English Transla		ent (if a	•
5. Oath or Declaration	Total Pages 3	1	12.	Information Dis- Statement (IDS			Copies of IDS Citations
a. Newly execu	uted (original or copy)		13.				- 10.00
b. Copy from a (for continua	prior application (37 CFR 1.63 (d)) tion/divisional with Box 18 completed)		14.	Return Receipt (Should be spec	Postcard (N	IPEP ( zed)	503)
· · · · · · · · · · · · · · · · · · ·	ION OF INVENTOR(S) tement attached deleting inventor(s)		15.	Certified Copy (if foreign priori			nt(s)
	he prior application, see 37 CFR		16.	☐ Nonpublication			
1.63(d)(2)	and 1.33(b).		10.	→ (b)(2)(B)(i). Appr	olicant must a		form PTO/SB/35
6. Application Data	Sheet. See 37 CFR 1.76		I	or its equivalen	t.		
replication but			17.	Other:		• • • • • • • • • • • • • • • • • • • •	****
or in an Application Data She	CATION, check appropriate box, and	supply t	the requi	site information belo	ow and in a p	prelimi	nary amendment,
Continuation X	Divisional Continuation-in-part (C	יופוי	n.f	prior application No	08 / 94	15 2	80
Prior application information	1	211 <i>j</i>			1644		<u> </u>
* *	Examiner LUDET  ONAL APPS only: The entire disclosure	of the n		Group Art Unit			a ic cumplied under
Box 5b, is considered a part of	the disclosure of the accompanying co	ntinuatio	on or divi	sional application an	d is hereby ir	corpo	rated by reference.
The incorporation can only be	relied upon when a portion has been ina	dvertent	tly omitte	d from the submitted	application p	arts.	
	19. CORRESPO	NDEN	CE ADDI	RESS			
Customer Number or Ber Co	ode Label (Insert Customer No. or Atla	on bar coc	de label her	or 🗶	Correspon	dence a	ddress below
Name	Leon R. Yankwich, Esq.						
	YANKWICH & ASSOCIATES	3					
Address	130 Bishop Allen Drive						
City	Cambridge Sta			Massachusett	s Zip C	Code	02139
Country	U.S.A.	Teleph	none	(617) 491-434	.3 Fá	ЭX	(617) 491-8801
Name (Print/Type)	Thomas R. Berka, Ph.D		Regis	tration No. (Attori	neylAgent)		39,606
Signature	Thomas K. Be	16	0		Date	30	August 2001
¥ 31.0101.0	- I TUUIIVUU I\. NJU		~		I Date		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231



PTO/SB/17 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office, U.S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

**TOTAL AMOUNT OF PAYMENT** 

(\$)	355.0	00
------	-------	----

Complete if Known			
Application Number	(not yet assigned)		
Filing Date	(concurrently herewith)		
First Named Inventor	Rittershaus and Thomas		
Examiner Name	(not yet assigned)		
Group Art Unit	(not yet assigned)		
Attorney Docket No.	TCS-411.1P US-1		

METHOD OF PAYMENT	FEE CALCULATION (continued)					
1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES					
Deposit	Large Small Entity Entity					
Account Number 50-0268	Fee Fee Fee Fee Fee Description Fe	ee Paid				
Deposit Account Yankwich & Associates	code (\$) code (\$)	ee i aiu				
Name Annie A						
Charge Any Additional Fee Required Under 37 CFR 1 16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet					
Applicant claims small entity status. See 37 CFR 1 27	139 130 139 130 Non-English specification					
2. X Payment Enclosed: (check #2202)	- 147 2,520 147 2,520 For filing a request for ex parte reexamination					
Check Credit card Money Order Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action					
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action					
1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month					
Large Entity Small Entity	116 390 216 195 Extension for reply within second month					
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	117 890 217 445 Extension for reply within third month					
101 710 201 355 Helity Sling for	118 1,390 218 695 Extension for reply within fourth month					
106 320 206 160 Design filing fee 355.00	128 1,890 228 945 Extension for reply within fifth month					
107 490 207 245 Plant filing fee	119 310 219 155 Notice of Appeal					
108 710 208 355 Reissue filing fee	120 310 220 155 Filling a brief in support of an appeal					
114 150 214 75 Provisional filing fee	121 270 221 135 Request for oral hearing					
SUBTOTAL (4) (ft) OFF OO	138 1,510 138 1,510 Petition to institute a public use proceeding					
SUBTOTAL (1) (\$) 355.00	140 110 240 55 Petition to revive - unavoidable					
2. EXTRA CLAIM FEES Fee from	141 1,240 241 620 Petition to revive - unintentional					
Extra Claims below Fee Paid	142 1,240 242 620 Utility issue fee (or reissue)					
Total Claims 5 -20** = 0 X 9.00 = 00.00	143 440 243 220 Design issue fee					
Claims	144 600 244 300 Plant issue fee					
Multiple Dependent 135.00 =	122 130 122 130 Petitions to the Commissioner					
Large Entity Small Entity	123 50 123 50 Processing fee under 37 CFR 1 17(q)					
Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt					
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)					
102 80 202 40 Independent claims in excess of 3	146 710 246 355 Filing a submission after final rejection	]				
104 270 204 135 Multiple dependent claim, if not paid	(37 CFR § 1 129(a))	——[				
109 80 209 40 ** Reissue independent claims over original patent	149 710 249 355 For each additional invention to be examined (37 CFR § 1 129(b))					
110 18 210 9 ** Reissue claims in excess of 20	179 710 279 355 Request for Continued Examination (RCE)					
and over original patent	169 900 169 900 Request for expedited examination of a design application					
SUBTOTAL (2) (\$) 00.00	Other fee (specify)					
**or number previously paid, if greater. For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 00.00					

SUBMITTED BY				Complete (if	applicable)
Name (Print/Type)	Thomas R. Berka, Ph.D.	Registration No. (Attorney/Agent)	39,606	Telephone	(617) 491-4343
Signature	Thomas R. Berka			Date	30 August 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

# The first first first than the second second

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Rittershaus & Thomas

Serial No.:

not yet assigned

Filed:

concurrently herewith

Entitled:

MODULATION OF CHOLESTERYL ESTER

TRANSFER PROTEIN (CETP) ACTIVITY

Attorney Docket No.: TCS-411.1P US-1

### **Box Patent Application**

Asst. Commissioner for Patents Washington, D.C. 20231

### UTILITY PATENT APPLICATION TRANSMITTAL:

Division of U.S. Appln. Ser. No. 08/945,289

Prior Examiner: Lubet Prior Unit: 1644

- 1. Fee Transmittal form PTO/SB/17 (in duplicate).
- 2. Utility Patent Application Transmittal form PTO/SB/05.
- 3. Copy of prior application specification of 66 pages (including Abstract of the Disclosure).
- 4. Formal Drawings (12 sheets).
- 5. Copy of oath/declaration (pursuant 37 CFR §1.63(d)) and power of attorney filed in parent application.
- 6. Copy of recorded Assignments filed in parent application.
- 7. Sequence Listing;
  - (a) computer readable form (CRF), (b) paper copy, and (c) statements under 37 CFR 1.825.
- 8. Information Disclosure Statement (including form PTO-1449).
- 9. Preliminary Amendment.
- 10. Return receipt post card.
- 11. Check No. 2202 in the amount of \$ 355.00 to cover the application filing fee.

Respectfully submitted,

Thomas R. Buka

Leon R. Yankwich; Registration No. 30,237

Thomas R. Berka, PhD; Registration No. 39,606

Examiner: not yet assigned

Art Unit: not yet assigned

Attorneys for Applicant

YANKWICH & ASSOCIATES

130 Bishop Allen Drive

Cambridge, Massachusetts 02139

telephone: (617) 491-4343 telefax: (617) 491-8801

### CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. **EL164335375US**, in an envelope addressed to the Asst. Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on the date indicated below.

<u> (lugust 30, 200</u>1

Stephanie L. Leicht

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Examiner: not yet assigned

Art Unit: not yet assigned

Application of:

Rittershaus & Thomas

Serial No.:

not yet assigned

Filed:

concurrently herewith

Entitled:

MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) ACTIVITY

Division of U.S. Appln. Ser. No. 08/945,289

Attorney Docket No.: TCS-411.1P US-1

**Box Patent Application** 

Assistant Commissioner for Patents Washington, D.C. 20231

# <u>Transmittal of Sequence Listing, Computer Readable Form, and Amendment Pertaining</u> <u>Thereto For Invention Containing Nucleotide and/or Amino Acid Sequence</u> <u>Under 37 CFR §§1.821-1.825</u>

Sir:

Transmitted herewith please find: a diskette containing a computer readable form (CRF) copy of an amended Sequence Listing, a paper copy of the amended Sequence Listing, and a preliminary amendment for the patent application filed currently herewith this paper.

Applicants have assigned a separate identifier to each of the 9 sequences disclosed, as required by 37 CFR §§1.821-1.825.

Applicants verify the following:

- 1. The enclosed amended Sequence Listing and the computer readable form of the amended Sequence Listing for the above-identified patent application are the same in content, as required by 37 CFR §1.825(b);
- 2. The enclosed amended Sequence Listing for the above-identified patent application contains no new matter and does not go beyond the original disclosure of the application, as required by 37 CFR §1.825(a);

3. The enclosed amended Sequence Listing and the computer readable form of the amended Sequence Listing for the above-identified patent application are in a form and format in accordance with 37 CFR §§1.822, 1.823, and 1.824.

Respectfully submitted,

Leon R. Yankwich; Registration No. 30,237

Thomas R. Berka

Thomas R. Berka, PhD; Registration No. 39,606

Attorneys for Applicants

YANKWICH & ASSOCIATES

130 Bishop Allen Drive

Cambridge, Massachusetts 02139

telephone: (617) 491-4343 telefax: (617) 491-8801

### CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. **EL164335398US**, in an envelope addressed to the Asst. Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on the date indicated below.

August 30, 2001

Stephanie L. Leicht